Methylene Chloride

Methylene Chloride

SCHEMBL21632812

ClCCl.[H+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4356913-A2 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS Linnaeus Therapeutics, Inc. (US) 2024-04-24 EP disclosed
EP-3823617-B1 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS LINNAEUS THERAPEUTICS INC (US) 2024-03-06 EP disclosed
US-20230382896-A1 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS Linnaeus Therapeutics, Inc. (US) 2023-11-30 US disclosed
CN-117105994-A Synthesis method of 3' -O-methoxy guanosine 天津全和诚科技有限责任公司 2023-11-24 CN disclosed
US-11760749-B2 Enantiomerically purified GPER agonist for use in treating disease states and conditions Linnaeus Therapeutics, Inc. (US) 2023-09-19 US disclosed
US-20220033385-A1 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS Linnaeus Therapeutics, Inc. (US) 2022-02-03 US disclosed
EP-3823617-A1 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS Linnaeus Therapeutics, Inc. (US) 2021-05-26 EP disclosed
US-10934277-B2 Enantiomerically purified GPER agonist for use in treating disease states and conditions Linnaeus Therapeutics, Inc. (US) 2021-03-02 US disclosed
US-20200140417-A1 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS Linnaeus Therapeutics, Inc. (US) 2020-05-07 US disclosed
WO-2020023391-A1 ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS Linnaeus Therapeutics, Inc. (US) 2020-01-30 WO disclosed
CN-106458920-A Alkynyl indazole derivative and use thereof 千寿制药株式会社 2017-02-22 CN disclosed
CN-102382037-A Benzene propanoic acid compound and preparation method and medicine use thereof INST MATERIA MEDICA CAMS 2012-03-21 CN disclosed
CN-102372697-A Substituted miazines compound KBP BIOSCIENCES CO LTD 2012-03-14 CN disclosed
CN-100363624-C Compressor with foreign body collector MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2008-01-23 CN disclosed
CN-1688553-A Chemical process SMITHKLINE BEECHAM CORP (US) 2005-10-26 CN disclosed
CN-1576594-A Compressor with foreign body collector MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2005-02-09 CN disclosed
CN-1179133-C Compressor with foreign matter collector ���µ�����ҵ��ʽ���� 2004-12-08 CN disclosed
CN-1361359-A Compressor with foreign matter collector MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2002-07-31 CN disclosed
CN-1029970-C Pyrrolopyrimidine derivatives TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-10-11 CN disclosed
CN-1037513-A The preparation of Pyrrolopyrimidine derivatives and application TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1989-11-29 CN disclosed